The comprehension of the clinical impact of KRAS mutations in metastatic CRC patients started with the identification of exon 2 mutations as negative predictors of response to anti-EGFR moAbs as per cetuximab and panitumumab (8, 9). The gene discussed is KRAS; the disease is colorectal carcinoma.